Compare FMC Corp (FMC) vs Nebius Group NV (NBIS) Price & Performance

FMC Corporation (FMC) trades at $11.61, up 8.3% today, but remains in a challenging fundamental position with a net income margin of -72.93% and negative ROE of -80.78% for 2025. The company is actively restructuring, securing a $400 million minority investment from Tessenderlo Group and planning a $114 million property sale to reduce its $3.03 billion long-term debt. Technical indicators are bearish, with the stock trading near key support at $11. Recent news highlights progress on its new herbicide, rimisoxafen, including a regulatory submission to the EPA and a partnership with Corteva.

The outlook is cautious. While aggressive debt reduction and new product pipelines offer potential, deep losses and declining revenue pose significant risks. The analyst consensus is mixed (47.6% Buy, 50% Hold) with a $16 price target, suggesting modest upside if turnaround efforts succeed, but high execution risk remains the primary concern for investors.

NBIS trades at $171.75, down 11.46% over 24 hours amid broader tech sector volatility. The stock shows bearish technical signals with support at $174 and resistance at $197. Fundamentally, the company reported Q1 2026 EPS of -$0.23, beating expectations, while Q4 2025 missed. Revenue grew to $529.8M in 2025 with a strong net income margin of 93.09%. Recent news highlights a $1B compute deal with Reflection AI and positive analyst coverage despite recent price pressure.

Outlook remains positive with 87.5% analyst buy ratings and a $248 consensus price target, implying 44% upside. Key risks include competitive pressures from Meta's cloud capacity and high valuation multiples (P/E 77). The company's expansion into AI infrastructure and partnerships supports long-term growth, but investors should monitor execution on capacity build-out and margin sustainability.